2022
Benefits and harms of oral anticoagulants for atrial fibrillation in nursing home residents with advanced dementia
Ouellet GM, O'Leary JR, Leggett CG, Skinner J, Tinetti ME, Cohen AB. Benefits and harms of oral anticoagulants for atrial fibrillation in nursing home residents with advanced dementia. Journal Of The American Geriatrics Society 2022, 71: 561-568. PMID: 36310367, PMCID: PMC9957933, DOI: 10.1111/jgs.18108.Peer-Reviewed Original ResearchConceptsNursing home residentsAtrial fibrillationAdvanced dementiaHome residentsStroke riskLong-stay nursing home residentsMedicare Part D claimsDementia-related mortalityGuideline-recommended thresholdHarms of anticoagulationRetrospective cohort studyMultivariable survival analysisValvular heart diseaseRisk of deathPart D claimsMonths of lifeMinimum Data SetAnticoagulant discontinuationAnticoagulated individualsMean CHAVASc scoreCause mortalityMultivariable adjustmentOral anticoagulantsCohort studyThe association between beta‐blockers and outcomes in patients with heart failure and concurrent Alzheimer's disease and related dementias
Gilstrap L, Cohen A, Ouellet GM, Goyal P, Gladders B, Flint D, Skinner J. The association between beta‐blockers and outcomes in patients with heart failure and concurrent Alzheimer's disease and related dementias. Journal Of The American Geriatrics Society 2022, 71: 404-413. PMID: 36240493, DOI: 10.1111/jgs.18086.Peer-Reviewed Original ResearchConceptsHigh riskBB useHeart failureAlzheimer's diseaseLong-term mortality ratesConcurrent Alzheimer's diseaseBeta-blocker useReduced ejection fractionMedicare Part ARisk/benefitBB therapyEjection fractionContemporary patientsHFrEFHigh prevalenceSimilar riskMortality ratePatientsCognitive impairmentMortalityDiseaseADRDRiskTherapyOutcomes
2021
Anticoagulant Use for Atrial Fibrillation Among Persons With Advanced Dementia at the End of Life
Ouellet GM, Fried TR, Gilstrap LG, O’Leary J, Austin AM, Skinner JS, Cohen AB. Anticoagulant Use for Atrial Fibrillation Among Persons With Advanced Dementia at the End of Life. JAMA Internal Medicine 2021, 181: 1121-1123. PMID: 33970197, PMCID: PMC8111560, DOI: 10.1001/jamainternmed.2021.1819.Peer-Reviewed Original Research
2016
Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions
Allore HG, Zhan Y, Cohen AB, Tinetti ME, Trentalange M, McAvay G. Methodology to Estimate the Longitudinal Average Attributable Fraction of Guideline-recommended Medications for Death in Older Adults With Multiple Chronic Conditions. The Journals Of Gerontology Series A 2016, 71: 1113-1116. PMID: 26748093, PMCID: PMC4945884, DOI: 10.1093/gerona/glv223.Peer-Reviewed Original ResearchMeSH KeywordsAdrenergic beta-AntagonistsAgedAged, 80 and overCardiovascular DiseasesDrug PrescriptionsDrug Therapy, CombinationFemaleFollow-Up StudiesHumansMaleMedicareMultiple Chronic ConditionsPractice Guidelines as TopicRetrospective StudiesSurveys and QuestionnairesSurvival RateThiazidesTreatment OutcomeUnited StatesConceptsMultiple chronic conditionsAverage attributable fractionChronic conditionsAttributable fractionCardiovascular conditionsHeart failureMedicare Current Beneficiary Survey participantsRenin-angiotensin system blockersGuideline-recommended medicationsMore chronic conditionsAge-stratified modelsSystem blockersBeta blockersCardiovascular medicationsOral medicationsAtrial fibrillationMedication effectsMedicationsAge strataParticipant characteristicsOlder adultsSurvivalThiazidesBlockersAge
2015
Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study
Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. The BMJ 2015, 351: h4984. PMID: 26432468, PMCID: PMC4591503, DOI: 10.1136/bmj.h4984.Peer-Reviewed Original ResearchConceptsSerotonin-norepinephrine reuptake inhibitorsMultiple chronic conditionsSelective serotonin reuptake inhibitorsAdjusted hazard ratioRisk of deathCalcium channel blockersChronic conditionsHazard ratioΒ-blockersCohort studyReuptake inhibitorsAtrial fibrillationOlder adultsChannel blockersCardiovascular drugsSSRIs/serotonin-norepinephrine reuptake inhibitorsRenin-angiotensin system blockersNorepinephrine reuptake inhibitorsSerotonin reuptake inhibitorsCommon combinationRAS blockersSystem blockersStudy drugHeart failureThromboembolic disease
2013
Medicare and the 3‐Day Rule
Cohen AB. Medicare and the 3‐Day Rule. Journal Of The American Geriatrics Society 2013, 61: 2266-2267. PMID: 24329847, PMCID: PMC3869097, DOI: 10.1111/jgs.12579.Commentaries, Editorials and Letters